製品名:4-fluoro-7-hydroxy-2,3-dihydroinden-1-one

IUPAC Name:4-fluoro-7-hydroxy-2,3-dihydro-1H-inden-1-one

CAS番号:136191-16-7
分子式:C9H7FO2
純度:95%+
カタログ番号:CM244476
分子量:166.15

包装単位 有効在庫 価格(USD) 数量
CM244476-100mg in stock ƩǭƩ
CM244476-250mg in stock ĜĜǭ
CM244476-1g in stock ƏţĜ

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:136191-16-7
分子式:C9H7FO2
融点:-
SMILESコード:O=C1CCC2=C1C(O)=CC=C2F
密度:
カタログ番号:CM244476
分子量:166.15
沸点:
MDL番号:
保管方法:

Category Infos

New
Custom Organic Synthesis,Where to Buy Chemical Building Blocks - Chemenu
Pharmaceutical intermediates, bulk products, chiral, achiral, heterocycles, metal catalysts, amino acids, peptides, benzene, pyridine, pyrazine, triazine, piperidine, piperazine, morpholine, imidazoline, cyclopropane, indole, benzotriazole, anthranil, quinoline, naphthalene, boronic compounds, fluorination, oxidation, rearrangement reaction
Chemenu product lines cover amino acids and peptides, heterocyclic compounds, alkanes and aromatic compounds, carbohydrates, alcohols, aldehydes & ketones, pyridazines, metal catalysts and other pharmaceutical intermediates. For more custom organic synthesis, please contact us for a quote.
Benzenes
Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

Column Infos

Belzutifan
On September 19, MSD announced that the U.S. FDA has accepted and granted priority review for a supplemental new drug application (sNDA) seeking approval for Welireg (Belzutifan), Merck's oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, for the treatment of adult patients with advanced renal cell carcinoma (RCC). Welireg was the first HIF-2α inhibitor therapy approved in the U.S. and is currently approved for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated RCC, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors, not requiring immediate surgery.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.